Last reviewed · How we verify
Diazepam 2Mg encapsulated Tab
Diazepam 2mg is a benzodiazepine marketed by The University of Hong Kong for anxiety disorders, acute alcohol withdrawal, muscle spasm relief, and adjunctive seizure management. As an established pharmaceutical with one clinical trial and marketed status, it represents a mature, well-characterized therapeutic option. The drug's broad clinical utility across multiple indications reflects decades of clinical validation, though it faces modern competition from newer anxiolytics with improved safety profiles. Commercial significance remains stable within the benzodiazepine class, primarily driven by cost-effectiveness and physician familiarity rather than innovation. No revenue data or novel mechanism developments are reported, indicating this is a legacy formulation in routine clinical use.
At a glance
| Generic name | Diazepam 2Mg encapsulated Tab |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor (allosteric modulator) |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Management of anxiety disorders
- Short-term relief of symptoms of anxiety
- Symptomatic relief of acute alcohol withdrawal
- Relief of skeletal muscle spasm
- Adjunctive treatment in convulsive disorders
Boxed warnings
- WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNING
Common side effects
Drug interactions
- Opioids
- Phenothiazines
- Antipsychotics
- Anxiolytics/Sedatives
- Hypnotics
- Anticonvulsants
- Narcotic Analgesics
- Anesthetics
- Sedative Antihistamines
- Barbiturates
- MAO Inhibitors
- Other Antidepressants
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diazepam 2Mg encapsulated Tab CI brief — competitive landscape report
- Diazepam 2Mg encapsulated Tab updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI